^
Association details:
| Biomarker: | KMT2D mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia
Published date:
01/22/2021
Excerpt:
Cells from patients with mutated (N = 9) or wild-type KMT2D (N = 6) were treated with decitabine or chidamide alone or combined with ibrutinib in the CellTiter-Glo assay. KMT2D-mutated cells were more sensitive to decitabine (IC50, Mean ± SEM, 22.2 ± 3.9 vs. 73.6 ± 25.4 μM; p = 0.029; Figure...Ibrutinib and chidamide also demonstrated synergy in KMT2D-mutated cells at a lower dosage...KMT2D-mutated CLL showed impaired H3K4 methylation activity and increased sensitivity to decitabine in vitro. The addition of decitabine to ibrutinib may yield synergistic treatment for KMT2D-mutated CLL patients.
DOI:
10.1038/s41375-021-01124-5
